+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Drugs Market by Drug Class (Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents), Route of Administration (Injectable, Oral), Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Oncology Drugs Market by Drug Class (Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents), Route of Administration (Injectable, Oral), Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Oncology Drugs Market by Drug Class (Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents), Route of Administration (Injectable, Oral), Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896719
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oncology drugs market is witnessing transformative shifts as new treatment modalities, advanced diagnostics, and regulatory changes reshape the competitive landscape. Industry leaders are prioritizing innovation and adaptability to capture opportunities and address challenges across global oncology value chains.

Market Snapshot: Oncology Drugs Market Growth Overview

The oncology drugs market grew from USD 210.00 billion in 2024 to USD 225.54 billion in 2025. It is expected to continue expanding at a CAGR of 7.72%, reaching USD 328.16 billion by 2030. This sustained growth reflects the industry’s investment in cutting-edge therapies, tailored patient care pathways, and streamlined regulatory approval processes.

Scope & Segmentation of the Oncology Drugs Market

This research delivers in-depth analysis structured around critical market dimensions and regions, each influencing commercial strategies and product adoption:

  • Drug Classes: Chemotherapy agents, hormonal therapy agents, immunotherapy agents (CAR T-cell, checkpoint inhibitors), targeted therapy agents (monoclonal antibodies, small molecule inhibitors).
  • Routes of Administration: Injectable formulations (intramuscular, intravenous, subcutaneous), oral therapies.
  • Molecule Types: Biologics (monoclonal antibodies, vaccines), small molecules.
  • Indications: Blood cancers (acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma), solid tumors (breast, colorectal, lung, prostate, others).
  • End Users: Hospitals, research institutes, specialty clinics.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Regions: Americas (including United States, Canada, Brazil, Argentina), Europe, Middle East & Africa (featuring United Kingdom, Germany, United Arab Emirates, others), and Asia-Pacific (with China, India, Japan, Australia, Singapore, and more).
  • Covered Companies: Includes profiles on AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Roche Holding AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and several others.

Key Takeaways for Senior Leadership

  • Innovation in immunotherapy and targeted agents is prompting shifts in R&D focus and partnerships between biopharma and technology organizations.
  • Patient-centric approaches, including precision oncology and companion diagnostics, are increasingly guiding clinical protocol development and commercial strategy.
  • Regional policy variation and reimbursement models require tailored go-to-market strategies for optimal drug access and lifecycle management.
  • Adoption of digital health technologies is streamlining real-time monitoring, adherence, and data-driven optimization of therapy outcomes.
  • Expanding the usability of oral oncology drugs is contributing to new outpatient care models and reshaping distribution channel dynamics.
  • Competitive differentiation is increasingly achieved through pharmacoeconomic evidence, value-based pricing, and strong payer-provider partnerships.

Tariff Impact on the Oncology Drugs Market

Recent changes to United States tariff policies are prompting companies to reassess sourcing and production strategies. The resulting adjustments—ranging from increased domestic manufacturing to renegotiating supply chain contracts—have strategic significance for cost management and patient access. Collaboration with regulatory bodies and agile procurement practices is becoming central to success in this evolving tariff landscape.

Methodology & Data Sources

This report leverages a multi-source approach combining primary interviews with oncologists, regulators, and supply chain specialists, alongside secondary research from peer-reviewed journals, registries, and company disclosures. Analytical models were used to validate findings and forecast trends.

Why This Report Matters

  • Enables strategic planning by clarifying emerging treatment paradigms and regulatory shifts in the oncology drugs market.
  • Offers stakeholders actionable intelligence to strengthen portfolio development, operational resilience, and go-to-market strategies regionally and globally.
  • Supports decision-making with an integrated view of clinical, commercial, and logistical drivers shaping short- and long-term market trajectories.

Conclusion

The oncology drugs market is rapidly evolving, shaped by innovation, regulatory complexities, and regional differences. Decision-makers equipped with actionable insights from this report will be positioned to manage risks, leverage new opportunities, and advance effective oncology solutions for diverse patient needs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of personalized neoantigen vaccine platforms targeting tumor-specific mutations in solid cancers
5.2. Growing integration of ultra-sensitive liquid biopsy assays for minimal residual disease monitoring in hematologic malignancies
5.3. Expansion of CD19-targeted CAR T cell therapies into earlier lines of diffuse large B cell lymphoma treatment protocols
5.4. Emergence of next generation KRAS G12C and G12D inhibitors demonstrating durable responses across lung and colorectal cancers
5.5. Increasing partnerships between pharmaceutical companies and diagnostic developers for PD-L1 companion diagnostic co-development programs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oncology Drugs Market, by Drug Class
8.1. Introduction
8.2. Chemotherapy Agents
8.2.1. Alkylating Agents
8.2.2. Antimetabolites
8.3. Hormonal Therapy Agents
8.4. Immunotherapy Agents
8.4.1. CAR T-Cell Therapy
8.4.2. Checkpoint Inhibitors
8.4.2.1. CTLA-4 Inhibitors
8.4.2.2. PD-1/PD-L1 Inhibitors
8.5. Targeted Therapy Agents
8.5.1. Monoclonal Antibodies
8.5.1.1. Chimeric
8.5.1.2. Humanized
8.5.2. Small Molecule Inhibitors
8.5.2.1. Cyclin-Dependent Kinase Inhibitors
8.5.2.2. Tyrosine Kinase Inhibitors
9. Oncology Drugs Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intramuscular
9.2.2. Intravenous
9.2.3. Subcutaneous
9.3. Oral
10. Oncology Drugs Market, by Molecule Type
10.1. Introduction
10.2. Biologics
10.2.1. Monoclonal Antibodies
10.2.2. Vaccines
10.3. Small Molecules
11. Oncology Drugs Market, by Indication
11.1. Introduction
11.2. Blood Cancer
11.2.1. Leukemia
11.2.1.1. Acute Myeloid Leukemia
11.2.1.2. Chronic Lymphocytic Leukemia
11.2.2. Lymphoma
11.2.2.1. Hodgkin Lymphoma
11.2.2.2. Non-Hodgkin Lymphoma
11.3. Breast Cancer
11.4. Colorectal Cancer
11.5. Lung Cancer
11.6. Prostate Cancer
12. Oncology Drugs Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Research Institutes
12.4. Specialty Clinics
13. Oncology Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Oncology Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Oncology Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Oncology Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Agenus Inc.
17.3.3. Amgen Inc.
17.3.4. Après-demain SA
17.3.5. Aspen Pharmacare Holdings Limited
17.3.6. Astellas Pharma Inc.
17.3.7. AstraZeneca PLC
17.3.8. Bayer AG
17.3.9. BeiGene, Inc.
17.3.10. Bristol-Myers Squibb Company
17.3.11. C.H. Boehringer Sohn AG & Co. KG
17.3.12. Cipla Limited
17.3.13. Eli Lilly and Company
17.3.14. GSK plc
17.3.15. Johnson & Johnson Services, Inc.
17.3.16. Merck KGaA
17.3.17. Pfizer Inc.
17.3.18. Puma Biotechnology, Inc.
17.3.19. Roche Holding AG
17.3.20. Shorla Oncology
17.3.21. Sun Pharmaceutical Industries Ltd
17.3.22. Sutro Biopharma, Inc.
17.3.23. Takeda Pharmaceutical Company Limited
17.3.24. Viatris Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ONCOLOGY DRUGS MARKET: RESEARCHAI
FIGURE 28. ONCOLOGY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. ONCOLOGY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. ONCOLOGY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 199. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 202. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 203. CANADA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 204. CANADA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 205. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. CANADA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 208. CANADA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 209. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 210. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 211. CANADA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. CANADA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 216. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 217. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 218. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 219. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 220. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 221. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 224. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 225. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 226. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 227. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 228. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 229. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 236. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 237. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 238. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 239. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 242. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 243. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 244. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 245. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 250. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 251. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 252. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 253. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 258. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 259. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 260. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 261. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 262. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 263. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 326. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 327. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 328. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 329. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 330. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 331. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 334. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 335. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 336. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 337. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 338. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 339. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 340. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 341. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 342. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 343. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 344. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 345. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 346. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 347. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Après-demain SA
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Bristol-Myers Squibb Company
  • C.H. Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Roche Holding AG
  • Shorla Oncology
  • Sun Pharmaceutical Industries Ltd
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 225.54 Billion
Forecasted Market Value ( USD ) by 2030 $ 328.16 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Generic Oncology Drugs Market by Drug Type (Biologics, Small Molecule), Indication (Breast Cancer, Colorectal Cancer, Leukemia), Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2025-2030 - Product Image

Generic Oncology Drugs Market by Drug Type (Biologics, Small Molecule), Indication (Breast Cancer, Colorectal Cancer, Leukemia), Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Cancer Therapeutics & Supportive Care Drugs Market by Drug Type (Supportive Care, Therapeutics), Route Of Administration (Intramuscular, Intravenous, Oral), Mechanism Of Action, Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

Cancer Therapeutics & Supportive Care Drugs Market by Drug Type (Supportive Care, Therapeutics), Route Of Administration (Intramuscular, Intravenous, Oral), Mechanism Of Action, Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Oncology Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Oncology Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Drug Pipelines
  • 150 Pages
  • Global
From
Cancer Immunotherapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Cancer Immunotherapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From

About the Chemotherapy Agent Market

The Chemotherapy Agent market within the Healthcare Services sector is a rapidly growing industry. It is composed of a variety of products and services that are used to treat cancer and other diseases. These products and services include drugs, medical devices, and other treatments. The market is driven by the increasing prevalence of cancer and other diseases, as well as the development of new treatments and technologies. The Chemotherapy Agent market is highly competitive, with many companies offering a wide range of products and services. Companies in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Roche. These companies are constantly innovating and developing new products and services to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.